EUCTR2017-005158-12-DE进行中（未招募）1 期
TEAM-Trial: Targeting Epigenetic therapy resistance in AML with Bortezomib: A multi-centre matched threshold crossing phase II approach - TEAM-Trial
Ruprecht-Karls-University Heidelberg Medical Faculty, University Hospital0 个研究点目标入组 50 人开始时间: 2018年8月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •See protocol chapter 5.3
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 35
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •See protocol chapter 5.4
研究者
相似试验
已完成
2 期
TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With BortezomibAcute Myeloid LeukemiaNCT04173585University Hospital Heidelberg50
进行中（未招募）
1 期
Phase I/II ex vivo gene therapy clinical trial for RDEB using autologous skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector - EBGraftThe trial aims to treat the recessive dystrophic epidermolysis bullosa (RDEB) by grafting one to three subjects with RDEB with autologous COL7A1-modified skin equivalents, using SIN-RV encoding COL7A1 cDNA.MedDRA version: 20.0 Level: LLT Classification code 10074980 Term: Epidermolysis bullosa aquisita System Organ Class: 100000004858EUCTR2016-002790-35-FRINSERM3
招募中
不适用
Combination of molecularly-targeted therapy with stereotactic body radiotherapy in hepatocellular carcinoma with major vascular invasioHepatocellular carcinoma with major vascular invasionJPRN-UMIN000030718Osaka International Cancer Institute20
招募中
不适用
Beating EATL - towards rationally targeted therapy for enteropathy-associated T-cell lymphomaenteropathy-associated T-cell lymphomagluten intolerance1002532110025477NL-OMON55365Vrije Universiteit Medisch Centrum100
已完成
2 期
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is MetastaticRecurrent MelanomaStage IIIA MelanomaStage IIIB MelanomaStage IIIC MelanomaStage IV MelanomaNCT02094872Yale University49